Our top pick for
Sana Biotechnology, a company that develops platforms to replace or repair cells in our bodies, wrapped an upsized IPO at $588 million.Morgan Stanley, Goldman Sachs Group, JPMorgan and BofA Securities were the bookrunners for the deal.
|52-week range||$21.21 - $44.60|
|50-day moving average||$29.01|
|200-day moving average||$31.58|
|Wall St. target price||$41.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$0|
|Return on assets TTM||-25.47%|
|Return on equity TTM||-80.76%|
|Market capitalisation||$4.4 billion|
TTM: trailing 12 months
There are currently 2.6 million Sana Biotechnology shares held short by investors – that's known as Sana Biotechnology's "short interest". This figure is 163.1% up from 981,523 last month.
There are a few different ways that this level of interest in shorting Sana Biotechnology shares can be evaluated.
Sana Biotechnology's "short interest ratio" (SIR) is the quantity of Sana Biotechnology shares currently shorted divided by the average quantity of Sana Biotechnology shares traded daily (recently around 629885.85365854). Sana Biotechnology's SIR currently stands at 4.1. In other words for every 100,000 Sana Biotechnology shares traded daily on the market, roughly 4100 shares are currently held short.
To gain some more context, you can compare Sana Biotechnology's short interest ratio against those of similar companies.
However Sana Biotechnology's short interest can also be evaluated against the total number of Sana Biotechnology shares, or, against the total number of tradable Sana Biotechnology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sana Biotechnology's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Sana Biotechnology shares in existence, roughly 10 shares are currently held short) or 0.0301% of the tradable shares (for every 100,000 tradable Sana Biotechnology shares, roughly 30 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sana Biotechnology.
Find out more about how you can short Sana Biotechnology stock.
We're not expecting Sana Biotechnology to pay a dividend over the next 12 months.
Sana Biotechnology, Inc. , a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops in vivo and ex vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease; and SC187 for heart failures. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.